跳至主要内容
临床试验/NCT01227317
NCT01227317已完成不适用

Prognostic Value of Novel Biomarkers in Patients With Shortness of Breath Attending an Emergency Department

ThermoFisher Scientific Brahms Biomarkers France1 个研究点 分布在 1 个国家目标入组 444 人开始时间: 2010年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
444
试验地点
1
主要终点
prognostic value of PCT, MR proADM, Mr pro ANP, Copeptin and pro endothelin in SOB

研究概览

简要总结

The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine vasopressin), Pro endothelin to stratify the risk in severe dyspnea.

详细描述

In emergency department shortness of breath (SOB)is a common symptom and its cause is not easy to be identified. The risk stratifying remains a challenge, Prognostic value of biomarkers might be helpful.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • tachypnea > 25 /min or Pa02 < 70 mmHg or SpO2 < 93%
  • diagnosis suspected: CAP, PE,EACOPD, AHF

排除标准

  • other cause of dyspnea,
  • unreachable on Day 30

结局指标

主要结局

prognostic value of PCT, MR proADM, Mr pro ANP, Copeptin and pro endothelin in SOB

时间窗: at Day 30

all cause mortality or Intensive Care Unit(ICU) admission from inclusion to Day 30

次要结局

  • establish the diagnostic value of PCT and MR pro ANP(at admission)

研究者

发起方
ThermoFisher Scientific Brahms Biomarkers France
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验